In vivo genome editing of ANGPTL3: a therapy for atherosclerosis?

被引：10
|
作者：
Rhee, June-Wha [1 ,2 ]
Wu, Joseph C. [1 ,2 ,3 ]
机构：
[1] Stanford Cardiovasc Inst, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA
来源：
NATURE REVIEWS CARDIOLOGY | 2018年 / 15卷 / 05期
关键词：
DISEASE; DNA;
D O I：
10.1038/nrcardio.2018.38
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hyperlipidaemia is an important risk factor for coronary artery disease. Chadwick and colleagues report significantly reduced blood lipid levels following CRISPR-based in vivo genome editing in mice to introduce loss-of-function mutations in Angptl3, encoding a lipoprotein lipase inhibitor. Treatment was effective in both wild-type and Ldlr(-/-) mice and had a similar effect to that of Pcsk9-targeted genome editing, without causing off-target mutations.
引用
收藏
页码：259 / 260
页数：2
相关论文
共 50 条
  • [21] ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model
    Hurt-Camejo, Eva
    JOURNAL OF LIPID RESEARCH, 2020, 61 (03) : 272 - 274
  • [22] ANGPTL3研究进展
    李丙蓉
    郑宏庭
    邓华聪
    第三军医大学学报, 2005, (05) : 461 - 463
  • [23] Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3
    Zimerman, Andre
    Wiviott, Stephen D.
    Park, Jeong-Gun
    Murphy, Sabina A.
    Ran, Xinhui
    Bramson, Candace R.
    Curto, Madelyn
    Ramos, Vesper
    Jevne, Alexandra
    Kuder, Julia F.
    Verma, Subodh
    Wojakowski, Wojtek
    Terra, Steven G.
    Sabatine, Marc S.
    Bergmark, Brian A.
    Marston, Nicholas A.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2024, 18 (02) : e261 - e268
  • [24] The study of Angptl3 and Angptl4 in podocyte injury
    Liu, J.
    Shen, Q.
    Dai, R.
    Xu, H.
    PEDIATRIC NEPHROLOGY, 2016, 31 (10) : 1833 - 1833
  • [25] Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3
    Watts, Gerald F.
    Raal, Frederick J.
    Chan, Dick C.
    FUTURE CARDIOLOGY, 2021, 18 (02) : 143 - 153
  • [26] Metabolomic profiling of ANGPTL3 deficiency
    Tikkanen, E.
    Wurtz, P.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1110 - 1110
  • [27] Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3
    Qiu, Min
    Glass, Zachary
    Chen, Jinjin
    Haas, Mary
    Jin, Xin
    Zhao, Xuewei
    Rui, Xuehui
    Ye, Zhongfeng
    Li, Yamin
    Zhang, Feng
    Xu, Qiaobing
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (10)
  • [28] METABOLIC SIGNATURE OF ANGPTL3 DEFICIENCY
    Tikkanen, E.
    ATHEROSCLEROSIS, 2019, 287 : E287 - E287
  • [29] Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice
    Zuo, Yuanbojiao
    Zhang, Chen
    Zhou, Yuan
    Li, Haiwen
    Xiao, Weidong
    Herzog, Roland W.
    Xu, Jie
    Zhang, Jifeng
    Chen, Y. Eugene
    Han, Renzhi
    CELL AND BIOSCIENCE, 2023, 13 (01):
  • [30] An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models
    Lee, R.
    Denizio, J.
    Mizoguchi, T.
    Dutta, C.
    Clendaniel, V.
    Garrity, R.
    Cox, N.
    Glass, Z.
    Chamarthi, H.
    Braun, M.
    Jayaram, H.
    Rohde, E.
    Kathiresan, S.
    Bellinger, A. M.
    Khera, A. V.
    EUROPEAN HEART JOURNAL, 2023, 44
12345